In Merck Sharp & Dohme Corp. v. Hospira, Inc.,[1] the Federal Circuit affirmed the lower court’s ruling that the asserted claims of Merck’s U.S. Patent No. 6,486,150 (the ’150 patent) were obvious despite evidence of commercial success and copying by others. Concerned that the majority’s opinion constituted a shortcut around a proper Graham analysis, Judge
Latest Post
More Posts
The Federal Circuit Provides a Tutorial on Patent Venue
Federal Circuit Suggests Solution to Patent Owner’s Dilemma When Applicant for Biosimilar Product Refuses Discovery
The Federal Circuit Reverses a Hindsight Reconstruction of An Important Pharmaceutical Invention
The Federal Circuit Invalidates a Patent for Failure to Describe the Accused Product
The Supreme Court, Reversing the Federal Circuit, Holds that “Residence” in the Patent Venue Statute Refers to Only a Domestic Corporation’s State of Incorporation
In Case of First Impression, Federal Circuit Rules that a Patent Owner’s Statements in an IPR Proceeding Can Create Prosecution Disclaimer
Federal Circuit Remands Novel Issue on Patent Marking Requirement
Federal Circuit Appears to Narrow the Exceptions to 35 U.S.C. § 101
The Federal Circuit Considers a New Issue on Appeal, Lectures the PTO on its Burden to Establish Obviousness, and Reveals an Internal Split on What to do When the PTO Fails to Carry That Burden
Subscribe: Subscribe via RSS
Blogs
Firm/Org